Spravato®
Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.
Clinical trials have shown over 60% response rate, and 52% remission rate in patients treated with Spravato® with minimal side effects.